Andres Poveda, MD, on the Implications of the Phase 3 SOLO2/ENGOT-ov21 Trial

In an interview with CancerNetwork®, Andres Poveda, MD, of the Fundación Instituto Valenciano de Oncologia in Valencia, Spain, spoke about the benefits that the phase 3 SOLO2/ENGOT-ov21 trial lend to patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

The results of the trial, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, showed that maintenance olaparib (Lynparza) provided an unprecedented improvement in median overall survival versus placebo in this patient population.

Transcription:

Well, you know, in regard to the patient, overall survival improving more than 1 year is impressive. It’s something that we have never seen before. The second is that, in my opinion, that patients can make a regular life because the maintenance therapy is… they’re by tablets, so regular life is really something that for the patients is absolutely important in order to avoid going to the hospital frequently. The tolerability is good, so safety is okay. So, we presented data on overall survival because we make it long term regarding the paper with PFS 2 years, and it’s more or less the same tolerance. I think that also, a relevant finding is the time to subsequent treatment. That means that patients delaying, they need to subsequent treatment. Not only overall survival is crucial, but time to subsequent treatment is also crucial because it means that patients can… and wait for some new chemotherapy treatment.